Formulation and systemic therapy
- 29 July 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2173-2175
Abstract
This case describes a young patient presenting with severe chronic hand eczema despite topical corticosteroid treatment with a preference for nonsystemic treatment. She has a Dermatology Life Quality Index (DLQI) score of 12. She has marked clinical improvement after 8 months of topical delgocitinib treatment, demonstrating the emerging role of topical pan-Janus kinase inhibitors as second-line therapy.Keywords
This publication has 4 references indexed in Scilit:
- Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trialThe Lancet, 2025
- Topical delgocitinib for the treatment of chronic hand eczemaJournal of Dermatological Treatment, 2025
- Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA–CHE): a new clinician reported outcome measure of CHE severityArchives of Dermatological Research, 2024
- Guidelines for diagnosis, prevention, and treatment of hand eczemaContact Dermatitis, 2021